Today, we have the pleasure to announce that a patent for the core technology behind our tissue platform Nexocyte and our high-resolution 3D bioprinting system Biopixlar has been granted in the EU.
The granted patent is an important step forward that lets us further advance our mission to provide the next generation of tissue solutions for drug development and regenerative medicine, changing the way we treat diseases.
Fluicell holds 19 patents, grouped in five patent families, covering our unique microfluidic technology and its application in high-resolution bioprinting. Read more about Fluicell’s patent on our intellectual property page.